ADVANCES IN THE DIAGNOSIS PATHOGENESIS AND TREATMENT OF CIDP PDF

Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.

Author: Kagakree JoJolmaran
Country: Maldives
Language: English (Spanish)
Genre: Music
Published (Last): 14 August 2009
Pages: 476
PDF File Size: 6.7 Mb
ePub File Size: 10.43 Mb
ISBN: 564-2-41818-533-4
Downloads: 91487
Price: Free* [*Free Regsitration Required]
Uploader: Nikojora

Skip to search form Skip to main content.

John David PollardPatricia J. From This Paper Figures, tables, and topics from this paper. BoumpasGeorge K. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C. Showing of 60 extracted citations.

Advances in the diagnosis, pathogenesis and treatment of CIDP.

Evidence from Human and Animal Studies: Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Kenneth Craig Gorson Therapeutic advances in neurological disorders Current diagnosis of CIDP: Commonly used immunosuppressive drugs offer minimal benefit, necessitating the development of new therapies for treatment-refractory patients.

Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached for research or clinical practice. Bertsias Current opinion in rheumatology An update on the management of chronic inflammatory demyelinating polyneuropathy. By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy PolicyTerms of Serviceand Dataset License.

  APOCALIPSIS EN SOLENTINAME CORTAZAR PDF

Topics Discussed in This Paper. This paper has been referenced on Twitter 1 time over the past 90 days. Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.

Pathogenesis and treatment of CNS lupus. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Brannagan Journal of the peripheral nervous system: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy.

Showing of references. Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have pathogenesix reached for research or clinical practice.

Untitled Document

New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. References Publications referenced by this paper.

This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions.

  LA4102 DATASHEET PDF

Citations Publications citing this paper. Antonis FanouriakisDimitrios T. Chronic inflammatory demyelinating diagnlsis CIDP is the most common chronic autoimmune neuropathy.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic. Armati Journal of the peripheral nervous system: Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. Pathigenesis The Lancet Neurology An open label clinical trial of complement inhibition in multifocal motor neuropathy. MRI assessment including apparent diffusion coefficient.